An MD An­der­son study points to an­oth­er use for No­var­tis’ GSK-born can­cer drugs

Though ap­proved, the pre­ci­sion on­col­o­gy drugs No­var­tis grabbed in the famed can­cer-for-in­fec­tious dis­ease swap with Glax­o­SmithK­line are still in stud­ies for new pop­u­la­tions and they’ve con­tin­ued to find ef­fi­ca­cy in new pa­tients.

That in­clud­ed tri­als com­bin­ing the BRAF in­hibitor Tafin­lar with the MEK in­hibitor Mekin­ist. Ear­li­er this year, at AS­CO, No­var­tis showed that a Tafin­lar-Mekin­ist com­bo led to a 43% com­plete re­sponse rate in ad­vanced melanoma pa­tients when com­bined with Keytru­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER